Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus PF chemotherapy and local radiotherapy for first-line recurrent/metastatic head and neck squamous cell carcinoma
ChiCTR2200067129Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jan 2023
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, cisplatin and fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
cadonilimabcisplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2200067129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067129.